Comekibart clinical trials
Also written MG-K10.
How each study uses comekibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the comekibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MG-K10
- 4
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Shanghai Mabgeek Biotech.Co.Ltd (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test comekibart, phase 3 first.
- Jan 2027A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic DermatitisPhase 3 · Shanghai Mabgeek Biotech.Co.Ltd
- May 2027A Phase 2 Study of MG-K10 in Chronic Spontaneous UrticariaPhase 2 · Shanghai Mabgeek Biotech.Co.Ltd
Studies
Open first, then newest update. How each study uses comekibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingPhase 3Shanghai Mabgeek Biotech.Co.LtdNCT07903194Written as MG-K10
- A Phase 2 Study of MG-K10 in Chronic Spontaneous UrticariaNot yet recruitingPhase 2Shanghai Mabgeek Biotech.Co.LtdNCT07838727Written as MG-K10 Injection
- A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic DermatitisNot yet recruitingPhase 3Shanghai Mabgeek Biotech.Co.LtdNCT07540442Written as MG-K10 Injection (Humanized Monoclonal Antibody)
- IB/IIa Study of MG-K10 in Adolescent Moderately Severe PatientsRecruitingPhase 1/2Shanghai Mabgeek Biotech.Co.LtdNCT06765005Written as MG-K10
- A Study of MG-K10 in Subjects With AsthmaRecruitingPhase 1/2Shanghai Mabgeek Biotech.Co.LtdNCT05382910Written as MG-K10
- A Study of MG-K10 in Subjects With Atopic DermatitisActive, not recruitingPhase 2Shanghai Mabgeek Biotech.Co.LtdNCT05466877Written as MG-K10
Codes
What other systems call comekibart · ClinicalTrials.gg INT016061
- UNII (FDA) B343W7ZE23COMEKIBARTOne source FDA
- NCI Thesaurus C206895ComekibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B343W7ZE23 | COMEKIBART | One source FDA |
| NCI Thesaurus | C206895 | Comekibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.